Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Aptevo Therapeutics Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 27 | 27 | 0 |
| Shares | 795.6K | 867.6K | +71.9K (+9.0%) |
| Value | $2.85M | $2.63M | −$213.0K (−7.5%) |
New holders (3)
Institutions that held Aptevo Therapeutics Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cantor Fitzgerald, L. P. | 133,700 | $406.0K | 0.01% |
| Citadel Advisors LLC | 16,776 | $51.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,808 | $9.00K | 0.00% |
Sold out (3)
Institutions that held Aptevo Therapeutics Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Barclays PLC | 79,001 | $283.0K |
| Veritable, L.P. | 15,722 | $56.0K |
| FMR LLC | 155 | $1.00K |